The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


News Update

Threat Detection Company Forms Partnership to Advance Covid-19 Pathogen Screening

News Update
  ()
Patriot One Technologies reported it is collaborating with ecoMine Technologies to advance pathogen screening applications as part of Canada's Digital Technology Supercluster's Covid-19 program. read more >

Altimmune Shares Up 20% Upon Forming Partnership for Intranasal COVID-19 Vaccine

  ()
Altimmune shares reached a new 52-week high after the company reported it is collaborating with DynPort Vaccine on U.S. government funding efforts for AdCOVID™, its COVID-19 vaccine candidate. read more >

Biotech with Phase 3 Rheumatoid Arthritis and Psoriasis Trials Raises Capital, Now 'Funded Through Catalysts'

Research Report
  ()
An update on Can-Fite BioPharma's multiple drug treatment trials is provided in a Dawson James report. read more >

Preclinical COVID-19 Vaccine Data 'Encouraging'

Research Report
  ()
Updates on Sorrento Therapeutics' two coronavirus-related products are provided in an H.C. Wainwright & Co. report. read more >
News Update

Biopharma Starts Enrollment Screening for Phase 2 Pulmonary Fibrosis, Cough Trial

News Update
  ()
In the study, Algernon Pharmaceuticals will test an existing drug that is being repurposed for these indications. read more >

Analyst: G1 Minimizes the Carnage of Chemotherapy

Research Report
  ()
ROTH Capital Partners initiates coverage on U.S. oncology biopharma G1 Therapeutics that is now filing an NDA. read more >

'Undervalued' Biopharma Gets Breakthrough Status for Alzheimer's Agitation Drug

Research Report
  ()
Axsome Therapeutics' latest news and clinical outlook are discussed in an H.C. Wainwright & Co. report. read more >

Akero Therapeutics Shares Rise on Positive Data from Phase 2a NASH Study

  ()
Akero Therapeutics shares traded 28% higher and established a new 52-week high after the company reported that it recorded positive histological data across all Efruxifermin dosage groups in its Phase 2a BALANCED Study in NASH patients. read more >
News Update

Life Sciences Firm Submits IND Application to FDA for Phase 3 COVID-19 Study

News Update
  ()
Revive Therapeutics submitted an Investigational New Drug Application to the FDA for a Phase 3 confirmatory study of Bucillamine for treatment in SARS-CoV-2. read more >
News Update

Biopharma's Multinational COVID-19 Study Receives US Ethics Approval

News Update
  ()
Algernon Pharmaceuticals is seeking approved participation from Australia, Romania and the Philippines as well. read more >

Vaxart Shares Rise 95% After Signing Agreement for Oral Tablet COVID-19 Vaccine

  ()
Shares of Vaxart Inc. nearly doubled after the company reported that it has signed a Memorandum of Understanding with Attwill Medical Solutions Sterilflow to enable production of a billion or more tablet COVID-19 vaccine doses annually. read more >

Biotech's New Mesothelioma Trial Data Show Efficacy, Immunogenicity

Research Report
  ()
These results of a study evaluating Targovax's lead candidate are reviewed and commented on in an H.C. Wainwright & Co. report. read more >

Translate Bio and Sanofi Expand Partnership to Develop mRNA Vaccines

  ()
Translate Bio shares traded 45% higher reaching a new 52-week high after the company reported that it is expanding its collaboration with Sanofi Pasteur to develop mRNA vaccines across all infectious disease areas. read more >

FDA Grants Ampio Pharma Approval to Begin Phase 1 Trial in COVID-19 Patients

  ()
Ampio Pharmaceuticals' shares traded higher after the company reported that the FDA cleared the firm to proceed with human trials of its Investigative New Drug application for intravenous AmpionTM for treatment in COVID-19 affected patients on supplemental oxygen. read more >

Alpine Immune Shares Soar 160% on Global Option and License Agreement with AbbVie

  ()
Shares of Alpine Immune Sciences set a new 52-week high after the company reported that it entered into an exclusive worldwide option and license agreement with AbbVie Inc. to develop and commercialize ALPN-101. read more >

Biopharma Launches Trial Testing Nitric Oxide as COVID-19 Treatment

Research Report
  ()
The design, timeline and takeaways of Beyond Air's study are presented in a ROTH Capital Partners report. read more >

Eli Lilly Trades Up 15% on Positive Phase 3 Breast Cancer Trial Results

  ()
Eli Lilly shares set a new 52-week high price after the company reported that its Verzenio® (abemaciclib) significantly reduced the risk of cancer returning in people with high risk HR+, HER2- early breast cancer. read more >

Edesa Shares Double Upon Gaining Approval to Initiate Phase 2/3 COVID-19 Study

  ()
Shares of Edesa Biotech traded more than 100% higher after the company reported that it had received regulatory approval from Health Canada to initiate a Phase 2/3 study of its investigational drug EB05 in COVID-19. read more >
News Update

Life Sciences Firm Expands Collaboration Efforts with Major U.S. University to Develop Psilocybin-Based Medicines

News Update
  ()
Revive Therapeutics Ltd. reported it has expanded its research partnership for novel formulation development and clinical research of psilocybin with the University of Wisconsin-Madison. read more >

Reata Pharma Announces $350 Million Strategic Investment from Blackstone Life Sciences

  ()
Shares of Reata Pharmaceuticals traded 30% higher after reporting that Blackstone Life Sciences will invest $350 million in the company to advance bardoxolone methyl as a potential therapy for Alport syndrome and other rare and serious chronic kidney diseases. read more >
News Update

Life Sciences Firm Pursues Phase 3 COVID-19 Treatment Trial in Canada

News Update
  ()
Revive Therapeutics met with Health Canada to discuss how best to proceed. read more >

Curis' Shares Take Off as FDA Clears IND Application for Monoclonal Anti-VISTA Antibody

  ()
Curis Inc. shares are up more than 130% and established a new 52-week high price after reporting that the FDA cleared the company's IND Application for CI-8993, its monoclonal anti-VISTA antibody. read more >

Enochian Shares Trade Up 50% upon Concluding FDA Meeting for Potential HIV Cure

  ()
Shares of Enochian Biosciences reached a new 52-week high after the company reported that it successfully completed its FDA INTERACT meeting for ENOB-HV-01, a potential cure for HIV. read more >
News Update

FDA Greenlights Biopharma for Trial of Possible COVID-19 Therapeutic

News Update
  ()
Algernon Pharmaceuticals prepares to commence the Phase 2b study as soon as possible. read more >

Immunotherapy Firm Releases Data Showing Treatment Potential Against Sepsis

Research Report
  ()
Recently presented results from Enlivex Therapeutics' Phase 1b study in sepsis and their implications are reviewed in an H.C. Wainwright & Co. report. read more >
Showing Results: 1 to 25 of 110 Next

Get Our Streetwise Reports Resources Report Newsletter Free and be the first to know!

A valid email address is required to subscribe